HCW Biologics (HCW Biologics) Interest Expense : $-0.19 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. HCW Biologics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. HCW Biologics's Operating Income for the three months ended in Mar. 2024 was $ -7.49 Mil. HCW Biologics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate HCW Biologics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HCW Biologics Interest Expense Historical Data

The historical data trend for HCW Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Interest Expense Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.51

-0.13

-0.28

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial													-0.09	-0.10	-0.10	-	-

HCW Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19 Mil.

HCW Biologics (NAS:HCWB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HCW Biologics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-7.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $8.27 Mil.

HCW Biologics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate HCW Biologics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

HCW Biologics (HCW Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057